AMSTERDAM, NETHERLANDS – 28 October 2021 — Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index today announces that the Company was awarded Best Poster at Hanson Wade’s 2021 World ADC Conference. Separately, Synaffix was also awarded ‘Runner-Up’ for the Best ADC Platform Technology.
New data presented in the winning poster, titled: “GlycoConnect™ ADCs Based on Topoisomerase 1 Inhibitor Exatecan (SYNtecan E™) Show Excellent In Vivo Efficacy and Tolerability Data” demonstrated complete tumor regression and high tolerability of SYNtecan E™ based ADCs, and underscores the ability of Synaffix’s technologies to enable best-in-class,
next generation ADCs.
This marks the fifth year that Synaffix’ groundbreaking ADC platform technology has been acknowledged at the World ADC Awards ceremony as industry-leading, by a judging panel of world-renowned ADC experts. The 2021 finalists were shortlisted through a voting pool of over 2,500 individuals, with a panel of distinguished, independent industry experts from across the ADC field assessing each finalist to decide the winners.
Prof. Floris van Delft, CSO of Synaffix, said: “The SYNtecan E™ linker-payload represents a transformational innovation that emerged from our own laboratories here in the Netherlands. This appreciation by our industry peers serves as yet another testament to the high-quality science that underlies our broader ADC platform technology offering and we look
forward to continuing the close collaboration with our various partners as this linker-drug enters the clinical development phase.”
For more information, please contact:
Vice President, Business Development
Optimum Strategic Communications
Hollie Ville, Stella Lempidaki, Vici Rabbetts
+44 (0) 208 078 4357
Notes to Editors
About Synaffix B.V.
Synaffix B.V. is a biotechnology company that enables ADC product candidates using its clinical-stage, site-specific ADC technology platform based on GlycoConnect™, HydraSpace™ and toxSYN™ that together enable any company with an antibody to develop proprietary best-in-class ADC products under a single license from Synaffix. The Synaffix platform enables a rapid timeline to clinic due to the established supply chain of technology components. Granted patents covering Synaffix’ technology provide end-to-end protection of the manufacturing technology as well as the resulting products through at least.
The business model of Synaffix is target-specific technology out-licensing, as exemplified through its existing deals with ADC Therapeutics, Mersana Therapeutics, Shanghai Miracogen, Innovent Biologics, ProfoundBio and Kyowa Kirin.
Synaffix is backed by a top tier, life science-focused investor syndicate that includes Aravis, BioGeneration Ventures, BOM Capital and M Ventures.
For more information, please visit the website at www.synaffix.com.
About The Synaffix ADC Platform Technology
Synaffix’ proprietary ADC technology platform consists of GlycoConnect™, HydraSpace™ and toxSYN™ technologies. Both GlycoConnect™ and HydraSpace™ are clinical-stage technologies that enable best-in-class ADCs with significantly enhanced efficacy and tolerability.
GlycoConnect™ is a conjugation technology that exploits the native antibody glycan for site-specific and stable payload attachment and is tunable to DAR1, DAR2 or DAR4 formats. HydraSpace™ is a compact and highly polar spacer technology that is designed to further enhance therapeutic index, particularly with hydrophobic payloads. toxSYN™ is a linkerpayload platform that spans key, validated MOAs for ADC product development, including SYNtecan E™ and SYNeamicin G™, among other linker-payloads. The combination of these three technologies provides developers with a “one stop” and easyto-use ADC technology platform, allowing any antibody developer to develop its own proprietary ADC and any ADC developer to expand its pipeline further and increase its competitive position.